Careers  |  Sign In  |  Register

Combination Improves Responses in RCC After Progression on Immune Checkpoint Inhibitor

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell renal cell carcinoma (ccRCC). Dr. Lee states that patients in the trial exhibited a 55% objective response rate (ORR) based on RECIST criteria and a 52% ORR using RECIST v1.1 criteria. With most patients still receiving the treatment at the 12 month study cut off, Dr. Lee reports this combination resulted in a median progression-free survival of 11.7 months.

Learn more by clicking here.